Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21900224 | 0.85 | GNRHR (0.43) | GNRHRCYP3A4 | |
| SCHEMBL17870751 | 0.84 | GNRHR (0.44) | GNRHRCYP3A4 | |
| SCHEMBL30178407 | 0.84 | GNRHR (0.44) | GNRHRCYP3A4 | |
| SCHEMBL30178655 | 0.83 | GNRHR (0.45) | GNRHRCYP3A4 | |
| SCHEMBL28649424 | 0.83 | GNRHR (0.45) | GNRHRCYP3A4 | |
| SCHEMBL19873886 | 0.83 | GNRHR (0.45) | GNRHRCYP3A4 | |
| SCHEMBL21900242 | 0.82 | GNRHR (0.37) | GNRHRCYP3A4 | |
| SCHEMBL19873721 | 0.82 | GNRHR (0.47) | GNRHRCYP3A4 | |
| SCHEMBL28638744 | 0.82 | GNRHR (0.45) | GNRHRCYP3A4 | |
| SCHEMBL28638669 | 0.77 | GNRHR (0.39) | GNRHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | MC1R, CALCRL, BDKRB2 | GNRHR 215/4885CYP3A4 2314/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | GNRHR 201/4885CYP3A4 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.